Key Takeaways:
- Tumors evade immune detection by shedding MICA/MICB proteins from immune cells, allowing them to hide and proliferate.
- A new vaccine boosts MICA/MICB protein density on immune cells, blocking tumor evasion and enabling T/NK cells to attack cancer effectively.
- Tested in mice and rhesus macaques, the vaccine increased immune activity by 60% and reduced tumor growth by 40%.
- Targets a common evasion tactic across cancers, potentially working for breast, lung, and melanoma tumors.
- Human trials are planned to assess safety and efficacy a critical step toward transforming cancer into a manageable condition.
Cancer has been a thorn in the flesh of the medical sector for many years as scientists have been unable to come up with a cure for this deadly disease. One advantage these cells possess that makes them able to thrive and survive in the body for so long is that they are constantly dividing. Because they are abnormal cells, they do not respond to signals in the body indicating the time for their death. Another huge contributor to their ability to survive is the fact that they hide very well from immune cells – they are not detected by T cells and natural killer cells. This makes it easy for them to keep living, dividing, and spreading fast within the body.
Cancer News
This high survival rate of cancerous cells makes it difficult for cancer to be cured completely, rather it is only treated and managed. So far, the only existing procedures doctors have adopted to treat this condition are chemotherapy, surgery, and radiation treatment. Because of the high cost and risk involved with these procedures, many cancer patients do not survive long enough, hence, the increasing number of death cases caused by cancer.
Thankfully, scientists have not given up on their research to find better ways to treat cancer, including a cure, if possible. Recently, a team of researchers affiliated with multiple institutions in the U.S. and one in Japan, have developed a vaccine that works to hinder various types of cancer cells from initiating their defense mechanism.
Cancer cells’ defense mechanism
When the body detects a growing tumor, the immune system is alerted immediately. T cells and natural killer cells of the immune system are sent to the site of the growing tumor to kill them. However, this is not the case with cancerous tumors: once the immune cells arrive at the site of the tumors, the tumors cleave to the proteins – MICA and MICB – found on the surface of the immune cells – a process known as ‘shedding’ of the immune cells. The shedding of the immune cells by the tumors makes them able to be hidden and unable to be detected by the immune system, therefore, they keep surviving and dividing.
Where the vaccine comes in
The researchers worked on mouse and rhesus macaque models while developing the vaccine. When they tested it on the animals, they observed that on administering the vaccine, the density of the proteins found on the surface of the immune cells was raised, and this prevented the tumors from being able to cleave to them, thereby, unable to initiate the shedding process. The researchers describe this process as “inciting protective immunity”. In summary, the vaccine stops the tumors from carrying out their defense mechanism. This would go a long way in aiding the innovation of better treatment procedures, and possibly a cure.
The researchers note that they have tested the vaccine on animals so far, and are in the process of clinically trying it on humans to ensure its safety.
Clinical significance
If human trials confirm safety and efficacy, this vaccine could revolutionize cancer treatment by making tumors more vulnerable to immune attacks. With a vaccine like this that targets the key to the survival and dividing ability of cancerous cells, the world of medicine may soon be free from the effects of this thorn, cancer.
Related Reading:
Role of Mutated Tumor Suppressor Genes in Facilitating Cancer Cells Avoidance of the Immune System
Cancer Immunotherapy: The Cowpea Mosaic Virus Effective in Treating Cancer
Cancer Treatment: p53, a Tumor Suppressing Gene, Stabilized by Spider Silk
FAQs:
How does the vaccine stop tumors from hiding?
By increasing MICA/MICB proteins on immune cells, the vaccine prevents tumors from shedding these markers, making them visible to T/NK cells.
When will the vaccine be available for humans?
If human trials (slated for 2023-2025) confirm safety and efficacy, it could reach clinics by 2030.
Does this replace chemo or radiation?
Not yet. It’s designed to enhance existing therapies, though future combos might reduce reliance on harsh treatments.
Will it work for all cancers?
Early data suggest broad applicability, as MICA/MICB shedding is common in many cancers, but efficacy may vary by tumor type.
What makes this different from other immunotherapies?
Most immunotherapies target specific cancers (e.g., CAR-T for blood cancers). This vaccine tackles a universal evasion tactic, offering wider reach.
Conclusion
This discovery is one of a kind! Cancer has been a prominent life-threatening disease for way too long. And to make matters worse, it has no clear cure. However, the revelation from this discovery may turn things around for the better in the world of medicine.
References
Badrinath, S., Dellacherie, M.O., Li, A. et al. A vaccine targeting resistant tumours by dual T cell plus NK cell attack. Nature 606, 992–998 (2022). https://doi.org/10.1038/s41586-022-04772-4
